27812586|t|Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate
27812586|a|Herein, we report a new process that enables the gram-scale production of a fully synthetic anti-cancer vaccine for human use. This therapeutic vaccine candidate, named MAG-Tn3, is a high-molecular-weight tetrameric glycopeptide encompassing carbohydrate tumor-associated Tn antigen clusters and peptidic CD4(+) T-cell epitopes. The synthetic process involves (i) the stepwise solid-phase assembly of protected amino acids, including the high value-added Tn building blocks with only 1.5 equivalents, (ii) a single isolated intermediate, and (iii) the simultaneous deprotection of 36 hindered protective groups. The resulting MAG-Tn3 was unambiguously characterized using a combination of techniques, including a structural analysis by nuclear magnetic resonance spectroscopy. The four peptidic chains are flexible in solution, with a more constrained but extended conformation at the Tn3 antigen motif. Finally, we demonstrate that, when injected into HLA-DR1 - expressing transgenic mice, this vaccine induces Tn-specific antibodies that mediate the killing of human Tn-positive tumor cells. These studies led to a clinical batch of the MAG-Tn3, currently investigated in breast cancer patients (phase I clinical trial). The current study demonstrates the feasibility of the multigram-scale synthesis of a highly pure complex glycopeptide, and it opens new avenues for the use of synthetic glycopeptides as drugs in humans.
27812586	26	36	structural	T082	UMLS:C0026383
27812586	61	73	glycopeptide	T103	UMLS:C0017953
27812586	74	83	dendrimer	T103	UMLS:C1563732
27812586	90	109	anti-cancer vaccine	T103	UMLS:C0376659
27812586	212	231	anti-cancer vaccine	T103	UMLS:C0376659
27812586	236	241	human	T204	UMLS:C0086418
27812586	252	271	therapeutic vaccine	T103	UMLS:C0301521
27812586	289	296	MAG-Tn3	T103	UMLS:C1254351
27812586	325	348	tetrameric glycopeptide	T103	UMLS:C0017953
27812586	362	402	carbohydrate tumor-associated Tn antigen	T103	UMLS:C0003341
27812586	416	424	peptidic	T103	UMLS:C0030956
27812586	425	438	CD4(+) T-cell	T017	UMLS:C0039215
27812586	439	447	epitopes	T103	UMLS:C0003316
27812586	531	542	amino acids	T103	UMLS:C0002520
27812586	575	577	Tn	T103	UMLS:C0076765
27812586	746	753	MAG-Tn3	T103	UMLS:C1254351
27812586	833	843	structural	T082	UMLS:C0026383
27812586	856	895	nuclear magnetic resonance spectroscopy	T058	UMLS:C0877853
27812586	906	914	peptidic	T103	UMLS:C0030956
27812586	985	997	conformation	T082	UMLS:C1518960
27812586	1005	1016	Tn3 antigen	T103	UMLS:C0076765
27812586	1073	1080	HLA-DR1	T103	UMLS:C0019768
27812586	1083	1093	expressing	T038	UMLS:C1171362
27812586	1094	1109	transgenic mice	T204	UMLS:C0025936
27812586	1116	1123	vaccine	T103	UMLS:C0376659
27812586	1132	1154	Tn-specific antibodies	T103	UMLS:C0003241
27812586	1172	1179	killing	T038	UMLS:C0599733
27812586	1183	1188	human	T204	UMLS:C0086418
27812586	1189	1212	Tn-positive tumor cells	T017	UMLS:C0431085
27812586	1259	1266	MAG-Tn3	T103	UMLS:C1254351
27812586	1294	1307	breast cancer	T038	UMLS:C0006142
27812586	1318	1340	phase I clinical trial	T062	UMLS:C0282459
27812586	1440	1447	complex	T103	UMLS:C1704241
27812586	1448	1460	glycopeptide	T103	UMLS:C0017953
27812586	1512	1525	glycopeptides	T103	UMLS:C0017953
27812586	1529	1534	drugs	T103	UMLS:C0013227
27812586	1538	1544	humans	T204	UMLS:C0086418